Video

Dr. Shore on study of patient preference between darolutamide and enzalutamide in mCRPC

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial presented at the 2021 ASCO Annual Meeting. The study is a prospective, randomized, open-label, multicenter, crossover, trial that assessed patient preference between darolutamide (Nubeqa) and enzalutamide (Xtandi) in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer. Shore is medical director of the Carolina Urologic Research Center.

      © 2025 MJH Life Sciences

      All rights reserved.